TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6892711

Group type: EXPERIMENTAL
Intervention: Free milk supplement (190 ml daily for six school terms)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control group (no free milk)
Number of subjects: 581
Study: 31434111

Group type: EXPERIMENTAL
Intervention: Active homeopathic medicine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 28506540

Group type: EXPERIMENTAL
Intervention: Positive parenting program (12 individual sessions, observational sessions with live coaching and video feedback)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 26017649

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2% lidocaine without epinephrine
Number of subjects: 70
Study: 24337619

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 0
Study: 20597808

Group type: EXPERIMENTAL
Intervention: 10-week progressive resistance exercise training programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 20
Study: 19954587

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional White Light
Number of subjects: 120
Study: 18021143

Group type: EXPERIMENTAL
Intervention: Warm packs applied to the perineum (n = 360)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Standard care (n = 357)
Number of subjects: 717
Study: 15356044

Group type: EXPERIMENTAL
Intervention: PTU pretreatment (n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No pretreatment (n = 41)
Number of subjects: 80
Study: 11682422

Group type: EXPERIMENTAL
Intervention: IQB‐9302 (0.25%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine (0.25%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IQB‐9302 (0.5%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bupivacaine (0.5%)
Number of subjects: 12
Study: 9649059

Group type: EXPERIMENTAL
Intervention: Single dose of LMW heparin (nadroparin) 12,500 ICU AXa at the beginning of dialysis
Number of subjects: 9

Group type: COMPARATOR
Intervention: Priming dose of nadroparin 10,000 ICU AXa at the beginning of dialysis followed by a supplementary dose of nadroparin 2,500 ICU AXa at the beginning of the fifth hour of dialysis
Number of subjects: 9
Study: 7521582

Group type: EXPERIMENTAL
Intervention: Aprotinin in standard doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2672492

Group type: EXPERIMENTAL
Intervention: Diazemuls (10 mg)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Valium Mixed Micelles (10 mg)
Number of subjects: 224
Study: 338983

Group type: EXPERIMENTAL
Intervention: Rifampicin plus Dapsone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapsone (DDS)
Number of subjects: 0
Study: 31909868

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 494
Study: 31415411

Group type: EXPERIMENTAL
Intervention: Health management group (155 cases)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (145 cases)
Number of subjects: 300
Study: 29376240

Group type: EXPERIMENTAL
Intervention: Dingkun Dan
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fuke Zaizao Jiaonang (Control)
Number of subjects: 75
Study: 25633506

Group type: EXPERIMENTAL
Intervention: Miniperc
Number of subjects: 212

Group type: COMPARATOR
Intervention: Shockwave Lithotripsy (SWL)
Number of subjects: 212
Study: 23891702

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 0.5μg/(kg body weight) intravenously administered for 24h
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21716251

Group type: EXPERIMENTAL
Intervention: Neyromidin (ipidacrinum) used in intramuscular injections
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Neyromidin (ipidacrinum) introduced by local injection perineural therapy
Number of subjects: 58
Study: 19701041

Group type: EXPERIMENTAL
Intervention: Surgical success defined as absence of prolapse beyond the hymen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective cure (absence of bulge symptoms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of re‐treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall improvement and treatment success rating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definitions of success requiring all anatomic support to be proximal to the hymen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective cure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom burden and health-related quality of life
Number of subjects: 0
Study: 16731464

Group type: EXPERIMENTAL
Intervention: Proximal Atrial Triad
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Distal Atrial Triad
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ventricular Triad
Number of subjects: 36
Study: 14647880

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 150 micro g
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 300 micro g
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 11721100

Group type: EXPERIMENTAL
Intervention: Tirofiban (body-weight adjusted intravenous) for a mean period of 46 hours
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (matched group of 17 acute ischemic clinically stable stroke patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 35
Study: 9408710

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8334344

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Verapamil plus Renal Disease Basic-prescription (RDBP)
Number of subjects: 24
Study: 3557792

Group type: EXPERIMENTAL
Intervention: Rifampicin alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Rifampicin in combination with isoniazid
Number of subjects: 39
Study: 28470563

Group type: EXPERIMENTAL
Intervention: Qishen Yiqi Dripping Pills (QSYQ)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (regular medication only)
Number of subjects: 80
Study: 26114234

Group type: EXPERIMENTAL
Intervention: Group medical consultations (GMCs)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Individual medical visits (control)
Number of subjects: 122
Study: 25219130

Group type: EXPERIMENTAL
Intervention: Cupping + acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture + TDP
Number of subjects: 60
Study: 22626580

Group type: EXPERIMENTAL
Intervention: elocalcitol 75 μg/d
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: elocalcitol 150 μg/d
Number of subjects: 308

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study: 20838991

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for PMs
Number of subjects: 19
Study: 18389444

Group type: EXPERIMENTAL
Intervention: PillCam ESO 2
Number of subjects: 28

Group type: COMPARATOR
Intervention: EGD
Number of subjects: 28
Study: 17119719

Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 41
Study: 12932668

Group type: EXPERIMENTAL
Intervention: Concomitant alternating chemotherapy and radiation at the coordinating centre
Number of subjects: 293

Group type: COMPARATOR
Intervention: Concomitant alternating chemotherapy and radiation at the affiliated centres
Number of subjects: 293

Group type: COMPARATOR
Intervention: Radiation alone at the coordinating centre
Number of subjects: 293

Group type: COMPARATOR
Intervention: Radiation alone at the affiliated centres
Number of subjects: 293
Study: 11916762

Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg Fe/d, 4 d/wk for 16 wk)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 9699402

Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction facemask
Number of subjects: 20
Study: 8017306

Group type: EXPERIMENTAL
Intervention: Artificial neural networks for diagnosing anterior myocardial infarction
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Conventional electrocardiographic criteria for diagnosing anterior myocardial infarction
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Artificial neural networks for diagnosing inferior myocardial infarction
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Conventional electrocardiographic criteria for diagnosing inferior myocardial infarction
Number of subjects: 1107
Study: 3137218

Group type: EXPERIMENTAL
Intervention: Amitriptyline (primary depressives N = 13, secondary depressives N = 6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bupropion (primary depressives N = 12, secondary depressives N = 6)
Number of subjects: 37
Study: 31068215

Group type: EXPERIMENTAL
Intervention: Target temperature management at 33 °C
Number of subjects: 853

Group type: COMPARATOR
Intervention: Target temperature management at 36 °C
Number of subjects: 853
Study: 28143463

Group type: EXPERIMENTAL
Intervention: Wearable sensors monitoring training activity during gait-related balance exercise
Number of subjects: 10
Study: 25593015

Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly (Arm A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly plus sorafenib 400mg PO twice-a-day (Arm B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: p16-negative tumors
Number of subjects: 55

Group type: COMPARATOR
Intervention: Higher TGFβ1 levels
Number of subjects: 55
Study: 23826087

Group type: EXPERIMENTAL
Intervention: Intralesional meglumine antimoniate (i.l.MA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (i.l.MA) + non-silver dressing
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (i.l.MA) + silver dressing
Number of subjects: 83
Study: 21685644

Group type: EXPERIMENTAL
Intervention: Interactive VR distraction
Number of subjects: 68

Group type: COMPARATOR
Intervention: Passive VR distraction
Number of subjects: 68
Study: 19233678

Group type: EXPERIMENTAL
Intervention: Cardioblate group (mitral valve surgery plus biatrial modified radiofrequency Maze procedure)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (mitral valve surgery plus intensive rhythm control strategy)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cardioblate group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 16404038

Group type: EXPERIMENTAL
Intervention: Multimedia educational interface 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimedia educational interface 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 0
Study: 15596636

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system, 30 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased serum creatinine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal serum creatinine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low creatinine clearance (<60 mL/min)
Number of subjects: 0
Study: 11387278

Group type: EXPERIMENTAL
Intervention: Semen collection into 20 ml HEPES buffered Ham's F‐10 medium with 10% human serum albumin (group B)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Semen collection into sterile dry pots (group A)
Number of subjects: 114
Study: 9403642

Group type: EXPERIMENTAL
Intervention: EPO (200 U/kg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 28
Study: 8427643

Group type: EXPERIMENTAL
Intervention: Genuine merino sheepskin (WoolTec USA, Maspeth, NY)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Synthetic sheepskin
Number of subjects: 108
Study: 3595971

Group type: EXPERIMENTAL
Intervention: Group A: 1 mg of ONO-802 vaginal suppository every 3 hours (maximum of five suppositories)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group B: 1 mg of ONO-802 vaginal suppository (maximum of three suppositories)
Number of subjects: 48
Study: 30993934

Group type: EXPERIMENTAL
Intervention: Diabetic rabbits with contrast agent (DCA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy rabbits with contrast agent (NCA)
Number of subjects: 62
Study: 28422346

Group type: EXPERIMENTAL
Intervention: Double-arm elevation above shoulder level
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-arm elevation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Double-arm elevation below shoulder level
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single-limb leg extensions
Number of subjects: 10
Study: 26073498

Group type: EXPERIMENTAL
Intervention: Positive mood induction (positive imagery training; PIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (positive verbal training; PVT)
Number of subjects: 0
Study: 23320469

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.3% mouth rinse for 15 seconds
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorhexidine 0.2% mouth rinse for 30 seconds
Number of subjects: 20
Study: 21598886

Group type: EXPERIMENTAL
Intervention: Primary open reduction internal fixation (ORIF) by bioabsorbable screws via a Smith‐Petersen approach
Number of subjects: 24

Group type: COMPARATOR
Intervention: Closed reduction (conservative treatment)
Number of subjects: 24
Study: 19917956

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16510122

Group type: EXPERIMENTAL
Intervention: XRCC1 399Gln variant
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: T‐A haplotype of XRCC1 194 Trp and XRCC1 399Gln
Number of subjects: 292

Group type: COMPARATOR
Intervention: Other polymorphic loci
Number of subjects: 292
Study: 15570082

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.2 mg/m2/dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.6 mg/m2/dose
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 15
Study: 10976602

Group type: EXPERIMENTAL
Intervention: Habituation to an actor who talked to the infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habituation to an actor who reached for and swiped at something
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (infants only saw the person or object stimulus)
Number of subjects: 0
Study: 9549633

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg d-sotalol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg d-sotalol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg d-sotalol
Number of subjects: 24
Study: 8368471

Group type: EXPERIMENTAL
Intervention: 2 g cefamandole administered preoperatively
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Haemofiltration techniques (HF) in group 1
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cell separation techniques (CS) in group 2
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (group 3) with carotid surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Comparison of group 1 and group 2
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transfusion of autologous blood
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Operation time of more than 2.5 h during ECC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Additional administration of 1 g cefamandole before cardiopulmonary bypass
Number of subjects: 62
Study: 3085261

Group type: EXPERIMENTAL
Intervention: DDAVP intranasally (i.n.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DDAVP subcutaneously (s.c.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DDAVP intravenously (i.v.)
Number of subjects: 10
Study: 29180524

Group type: EXPERIMENTAL
Intervention: Omadacycline 300 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Omadacycline 450 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Omadacycline 600 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 26092476

Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 75 for extra small effect size (≤0.1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 25 for small effect size (0.2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 15 for medium effect size (0.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot trial sample size of 10 for large effect size (0.8)
Number of subjects: 0
Study: 24533664

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial target-driven management
Number of subjects: 3057

Group type: COMPARATOR
Intervention: Routine care of diabetes according to national guidelines
Number of subjects: 3057
Study: 24395987

Group type: EXPERIMENTAL
Intervention: Expression of emotional support messages
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Reception of emotional support messages
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Perceived bonding
Number of subjects: 237
Study: 20669674

Group type: EXPERIMENTAL
Intervention: TXLC + aspirin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: TXLC alone
Number of subjects: 89

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 89
Study: 17721640

Group type: EXPERIMENTAL
Intervention: Conventional knee rehabilitation program (quadriceps strengthening and TENS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hip oriented rehabilitation program (stretching, hip external rotators strengthening and TENS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of conventional knee and hip oriented rehabilitation programs
Number of subjects: 30
Study: 15730802

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (routine treatment and early rehabilitation for 28 days, followed by community rehabilitation for 6 months or specialized reinforcement training for 2 months)
Number of subjects: 902

Group type: COMPARATOR
Intervention: Control group (routine treatment and early rehabilitation for 28 days, followed by self-conducted rehabilitation training for 6 months)
Number of subjects: 902
Study: 11558795

Group type: EXPERIMENTAL
Intervention: Low CSF hypocretin levels (<100 pg/ml) in 32 of 38 patients (all HLA-positive)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CSF leptin levels and adjusted BMI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Normal hypocretin levels in 4 patients (2 HLA-negative)
Number of subjects: 72
Study: 9778000

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol intravenously (group 2)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Saline (groups 1 and 3)
Number of subjects: 250
Study: 7873494

Group type: EXPERIMENTAL
Intervention: Infusion of activated autologous peripheral blood lymphocytes (after cultivation with anti-CD3 antibody and IL-2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 3208665

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - fathers involved in care with early discharge (24-48 hours after birth)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group (CG) - traditional hospital postpartum care (5-6 days stay)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Non-Participating Group (NPG) - parents not interested in early discharge study
Number of subjects: 49
Study: 29986023

Group type: EXPERIMENTAL
Intervention: Autologous heparinized whole blood (AWB)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 21
Study: 29743098

Group type: EXPERIMENTAL
Intervention: HFNC at 30 l/min and 31 °C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HFNC at 60 l/min and 31 °C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HFNC at 60 l/min and 31 °C in patients with clinical FiO2 ≥ 45%
Number of subjects: 40

Group type: COMPARATOR
Intervention: HFNC at 30 l/min and 37 °C
Number of subjects: 40

Group type: COMPARATOR
Intervention: HFNC at 60 l/min and 37 °C
Number of subjects: 40
Study: 27515417

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24587110

Group type: EXPERIMENTAL
Intervention: Phonics instruction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Other treatment approaches (including reading fluency trainings, phonemic awareness instructions, reading comprehension trainings, auditory trainings, medical treatments, interventions with coloured overlays or lenses, sunflower therapy, motor exercises)
Number of subjects: 22
Study: 23114081

Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 20950476

Group type: EXPERIMENTAL
Intervention: 50 mg AMG 108
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 125 mg AMG 108
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 250 mg AMG 108
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 17623753

Group type: EXPERIMENTAL
Intervention: Endurance training (9 weeks, 5 days/week, 1 hour/day, 75% Vo(2peak))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pretraining trials (45% Vo(2peak) and 65% Vo(2peak))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Posttraining trials (ABT and RLT at 65% of pretraining and posttraining Vo(2peak), respectively)
Number of subjects: 8
Study: 15871319

Group type: EXPERIMENTAL
Intervention: Minipunch grafting (MPG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Split-skin grafting (SSG)
Number of subjects: 64
Study: 12419297

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 485

Group type: COMPARATOR
Intervention: Aspirin alone (control)
Number of subjects: 485
Study: 10327777

Group type: EXPERIMENTAL
Intervention: Yoga intervention group (n = 52)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 41)
Number of subjects: 93
Study: 8961324

Group type: EXPERIMENTAL
Intervention: Single bout of physical activity (weight lifting)
Number of subjects: 28